Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04325776 Recruiting - Clinical trials for Bone Metastatic Non-small Cell Lung Cancer

A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis

Start date: September 24, 2020
Phase: Phase 2
Study type: Interventional

AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell migration.

NCT ID: NCT04325763 Recruiting - Clinical trials for Stage III Non-small-cell Lung Cancer

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Start date: May 27, 2020
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

NCT ID: NCT04324164 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

NCT ID: NCT04324151 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

NCT ID: NCT04324125 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

NCT ID: NCT04323579 Recruiting - Lung Cancer Clinical Trials

Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection.

CLEARLY
Start date: July 1, 2018
Phase:
Study type: Observational

CLEARLY will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. It will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-LDCT, using bioinformatics techniques; (b) assess the prognostic role of CTCs including the role of cells epithelial mesenchymal transition (EMT) and (c) standardize a method for genomic analysis of CTCs for early detection of treatment resistance.

NCT ID: NCT04322890 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PIKACHU
Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

NCT ID: NCT04322617 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

ATHENA
Start date: March 24, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

NCT ID: NCT04322591 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

POSEIDON
Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

NCT ID: NCT04322578 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

CONFIRM
Start date: March 24, 2020
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer